MetaCap

Aptevo Therapeutics Inc. (APVO)

NASDAQ: APVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.4041-0.0098 (-2.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

APVO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$66.96
52-week range
0.377 – 25.56
Day range
0.3944 – 0.4249
Volume / Avg
148.73K / 132.90K
Beta
—

52-week range

$0.377$25.56

APVO stock today

Aptevo Therapeutics (APVO) closed at $0.4041 on Nov 20, down 2.37% (-$0.0098), versus the S&P 500's 3.70% decline. At this level, APVO sits near the bottom of its 52-week range of $0.377 to $25.56: 98.4% below the high and 7.2% above the low. Aptevo Therapeutics trades at 0.0x its trailing twelve-month earnings per share of $66.96.

Summary generated from market data by MetaCap's automated system. Methodology

About Aptevo Therapeutics

Company profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jeffrey G. Lamothe CA
Headquarters
Seattle, WA
Employees
33

Financial highlights

Full financials

Aptevo Therapeutics reported a net loss of $26.0 million, compared with a loss of $24.1 million a year earlier. Diluted earnings per share came in at -$87.27.

Aptevo Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$3.11M$12.29M
Growth———-74.67%+185.26%
Net income$-25.97M$-24.13M$-17.41M$8.03M$-28.46M
EPS (diluted)$-87.27$-31,460.23$-2,316.83$1.57$-6.07

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$25.50+6210.32%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $21.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-5.19 vs $-3.72
Surprise
-39.52%

APVO news

All APVO news

Aptevo Therapeutics peers

Health Care sector
APVO peer companies
CompanyPrice% ChgMarket capCompare
CAPSCapstone Holding Corp.1.44-9.15%$1.35Mvs APVO
CMNDClearmind Medicine Inc.2.63-17.68%$1.33Mvs APVO
ELABPMGC Holdings Inc.1.14-10.24%$1.33Mvs APVO
ARTLArtelo Biosciences Inc.1.39-4.14%$1.30Mvs APVO
JUNSJupiter Neurosciences Inc.1.24-18.75%$1.63Mvs APVO
PRFXPRF Technologies Ltd.0.4758-23.68%$1.66Mvs APVO
KALAKALA BIO Inc.2.71-10.28%$1.74Mvs APVO
GOVXGeoVax Labs Inc.1.81-5.24%$985.46Kvs APVO

Indexes, lists and sector

Aptevo Therapeutics stock FAQ

What is Aptevo Therapeutics's stock price today?

APVO last traded at $0.4041 as of Nov 20, 4:00 PM EST, down 2.37% on the day. Prices are delayed at least 15 minutes.

What is APVO's P/E ratio?

APVO trades at a trailing P/E ratio of 0.01.

Who is Aptevo Therapeutics's CEO?

Mr. Jeffrey G. Lamothe CA is the chief executive officer of Aptevo Therapeutics Inc., which has about 33 employees.

What is the APVO 52-week high?

The 52-week high for APVO is $25.56 and the 52-week low is $0.377. The stock is currently 98.4% below its high.

Compare APVO